Moderna News. See Also: Regeneron Antibody Cocktail Could Reach the Market in October

SARS-CoV-2 Virus Vaccines
On Monday Moderna (MRNA) started its Phase 3 clinical trial on 30,000 people with its product mRNA-1273.

Separately, in a press release Moderna announced a preclinical study evaluating its product mRNA-1273 has been published in The New England Journal of Medicine. This study . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.